EPM2A Antikörper (AA 243-331)

Produktnummer ABIN336090

Produktdetails anti-EPM2A Antikörper

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Bindungsspezifität: AA 243-331

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser EPM2A Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Enzyme Immunoassay (EIA)

Spezifität: The antibody recognizes EPM2A.

Kreuzreaktivität (Details): Species reactivity (tested):Human

Produktmerkmale: Synonyms: EPM2A, Laforin, EC=3.1.3.48, EC=3.1.3.16, Lafora PTPase, LAFPTPase

Aufreinigung: Protein-G affinity chromatography

Immunogen: Recombinant human EPM2A (aa 243-331) purified from E. coli

Klon: K2A3

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA. Western blot (1: 1,000 - 1: 2,000).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1.0 mg/mL

Buffer: PBS, pH 7.4, containing 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store the antibody undiluted at 2-8 °C for up to two weeks or (in aliquots) at -20 °C forlonger. Avoid repeated freezing and thawing.
Shelf life: one year from despatch.

Haltbarkeit: 12 months

Details zu EPM2A

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Andere Bezeichnung: Laforin (EPM2A Produkte)

Synonyme: TG-B antikoerper, Tg(TcraK,TcrbK)TG-BFlv antikoerper, EPM2 antikoerper, MELF antikoerper, laforin antikoerper, EPM2A, laforin glucan phosphatase antikoerper, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antikoerper, EPM2A antikoerper, Epm2a antikoerper

Hintergrund: Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy.Synonyms: EC=3.1.3.16, EC=3.1.3.48, EPM2A, LAFPTPase, Lafora PTPase, Laforin

Gen-ID: 7957

UniProt: O95278

Pathways: Cellular Glucan Metabolic Process